Mr. Áron Mészáros | Health Professions | Research Excellence Award
Hungarian University of Sport Science | Hungary
1
1
2
Citations
h-index
Documents
Featured Publications
Topological Methods in Nonlinear Analysis | Journal Article · 2025 ·
Hungarian University of Sport Science | Hungary
Citations
h-index
Documents
Post Graduate Institute of Child Health, India
Mansoura University, Egypt
Dr. Farid A. Badria is a distinguished Professor of Pharmacognosy at the Faculty of Pharmacy, Mansoura University, Egypt, where he also leads the Liver Research Lab (FAB-Lab). With a career spanning over three decades, he has emerged as a leading expert in natural products research, biomedical sciences, and translational medicine. His research portfolio encompasses phytochemistry, biotechnology, drug discovery, liver diseases, and diagnostic biomarker development. A globally recognized scholar, Dr. Badria’s academic contributions have earned him several prestigious awards, including recognition by Stanford University among the top 2% most-cited scientists in his field. He has held visiting positions at top institutions such as the University of Minnesota and University of Mainz, Germany. His work bridges academia and practical applications by emphasizing sustainable drug development from natural sources, making his research relevant both scientifically and industrially. In addition to his prolific publication record and extensive teaching responsibilities, Dr. Badria has played significant roles in academic governance and research ethics in Egypt. He is a member of multiple scientific organizations and has mentored numerous students and researchers. His commitment to scientific excellence, public health, and academic leadership makes him a worthy contender for the Best Researcher Award.
Professional Profile
Dr. Badria’s educational background reflects his deep expertise in pharmacognosy, cell biology, and natural product chemistry. He holds a Ph.D. in Microbial Transformations and Natural Products Chemistry from the University of Mississippi, USA, where he conducted groundbreaking research on microbial metabolism and structural elucidation of bioactive compounds. Prior to this, he earned a Master of Science in Pharmaceutical Cell Biology and Natural Toxins from the University of Minnesota, USA. His early graduate education also includes an M.Sc. in Pharmacognosy and Natural Products Chemistry from Mansoura University, Egypt, where he began his career as a dedicated researcher. Dr. Badria earned his undergraduate degree, a B.Sc. in Pharmaceutical Sciences, from the same institution. His rigorous academic training in both Egypt and the United States provided him with a comprehensive foundation in natural sciences, advanced analytical techniques, pharmacology, and biotechnology. This diverse and multidisciplinary academic formation has empowered him to investigate complex biomedical problems, develop novel therapeutic strategies, and mentor future generations of scientists in both theoretical and applied pharmaceutical sciences. His global educational experience has also facilitated international collaboration and innovation throughout his career.
Dr. Farid A. Badria has amassed extensive academic and professional experience, serving in various esteemed roles that have shaped pharmaceutical education and research in Egypt and abroad. At Mansoura University, he has held positions ranging from Assistant Professor (1990) to Full Professor (since 2000), and has served as Head of the Pharmacognosy Department, Head of Applied Drug Research, and Director of the Central Research Lab. As the founding head of the Liver Research Lab (FAB-Lab), he has led pioneering work on liver disorders, natural enzyme modulators, and phytotherapy. His international career includes Visiting Professorships in Medicinal Chemistry at the University of Minnesota (USA) and at Universität Mainz (Germany), where he contributed to research on marine-derived drugs, apoptosis, and biomarkers. He has also served as a consultant and research associate in the United States. Additionally, Dr. Badria has actively contributed to academic governance, including roles on the Supreme Pharmacy Council of Egypt, Clinical Pharmacy Program Committee, and Promotion Committee for Pharmacy Professors. His professional journey reflects a harmonious blend of research innovation, academic leadership, and societal impact. His contributions have not only enriched his institutions but also advanced pharmaceutical sciences at the global level.
Dr. Badria’s research interests are interdisciplinary and pioneering, integrating natural product chemistry, biotechnology, pharmacognosy, and modern therapeutic strategies. His major focus lies in identifying novel bioactive compounds from plants, marine organisms, and microbial sources for use in drug discovery and disease treatment. A core area of his research targets liver diseases, particularly fibrosis and hepatocellular carcinoma, using hepatoselective agents and early diagnostic biomarkers. He is also deeply involved in phytotherapy for skin and metabolic disorders, such as alopecia, hyperpigmentation, obesity, and diabetes, through the modulation of key enzymes like aldose reductase and glucosidase. Additionally, Dr. Badria has worked extensively on cancer diagnostics (particularly ovarian and liver cancer), retinal pathology, and viral infections using both biochemical and AI-based models. His work explores enzyme inhibition as a central therapeutic mechanism and includes studies on topoisomerase, tyrosinase, and hyaluronidase inhibitors. His holistic approach also extends to environmental research, where he has developed biomarkers to monitor marine and freshwater pollution. Overall, Dr. Badria’s research combines traditional natural medicine with cutting-edge biomedical technologies, positioning him at the forefront of translational pharmacognosy and integrative therapeutic sciences.
Dr. Badria possesses a comprehensive and advanced skill set in both laboratory and clinical research methodologies. His expertise in natural products chemistry is demonstrated through his extensive use of chromatographic and spectroscopic techniques (HPLC, NMR, MS, IR, UV) to isolate and characterize novel therapeutic compounds. He is highly skilled in microbial transformation, tissue culture, and biological screening assays for evaluating cytotoxicity, antiviral activity, and enzyme inhibition. His work with mammalian cell culture, tumor induction, cryogenic preservation, and plant tissue cloning reflects his deep command over pharmaceutical biotechnology. Dr. Badria also utilizes AI and computational tools in healthcare research for predictive modeling in liver cancer, obesity, and treatment decision-making. His knowledge of biomarker discovery is applied in both clinical diagnostics and environmental science, identifying indicators for diseases and pollutants in human and aquatic systems. He is adept at experimental design, pharmacological evaluation, and interdisciplinary collaboration. These skills enable him to translate theoretical insights into practical applications, particularly in liver disease therapy, cancer detection, and anti-inflammatory drug development. Dr. Badria’s methodological rigor and technical proficiency are key strengths that drive the success and innovation of his research programs.
Dr. Badria’s exceptional research achievements have been recognized with numerous prestigious awards and honors, both nationally and internationally. Most notably, he was cited by Stanford University among the top 2% most-cited scientists in Medicinal and Biomolecular Chemistry. He received the World Intellectual Property Organization (WIPO) Gold Medal in 2011 as the “Best Inventor in Egypt,” and the Third World Academy of Sciences (TWAS) Prize in 2013 for public science communication. His national accolades include multiple State Recognition Awards in Medicine from the Egyptian Academy of Science and Merit of First Class from the President of Egypt in 1998. Internationally, he was honored with the Khawarizmi International Award (Iran, 2000), the NAM S&T Fellowship, and fellowships from UNESCO and the Arab Development Fund. Dr. Badria is also a member of several elite scientific bodies including the American Association for the Advancement of Science (AAAS), New York Academy of Sciences, and the American Society of Pharmacognosy (ASP). These accolades highlight not only his research excellence but also his contributions to science policy, innovation, and knowledge dissemination across borders.
In conclusion, Dr. Farid A. Badria exemplifies the qualities of an outstanding researcher whose work transcends disciplinary boundaries and geographic limitations. His career is characterized by an unwavering commitment to scientific advancement, innovation in natural products research, and impactful contributions to public health, particularly in liver disease treatment and diagnostics. Through his leadership in research, education, and institutional development, he has significantly elevated the scientific standing of Mansoura University and Egypt at large. His global engagements, collaborative initiatives, and mentoring have further amplified the reach and relevance of his work. Dr. Badria’s legacy is built not only on his prolific academic output and technical expertise but also on his dedication to integrating traditional medicine with modern science for the betterment of human health. Given his comprehensive and influential body of work, he is undoubtedly a highly suitable candidate for the Best Researcher Award, representing the highest standards of research integrity, innovation, and social responsibility in the scientific community.
Synthesis and biological evaluation of certain α, β-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents
Authors: HI El-Subbagh, SM Abu-Zaid, MA Mahran, FA Badria, AM Al-Obaid
Journal: Journal of Medicinal Chemistry 43(15), pp. 2915–2921, 2000
Citations: 536
Synthesis and antitumor evaluation of some new 1,3,4-oxadiazole-based heterocycles
Authors: S Bondock, S Adel, HA Etman, FA Badria
Journal: European Journal of Medicinal Chemistry 48, pp. 192–199, 2012
Citations: 266
Melatonin, serotonin, and tryptamine in some Egyptian food and medicinal plants
Author: FA Badria
Journal: Journal of Medicinal Food 5(3), pp. 153–157, 2002
Citations: 266
Antioxidant and immunomodulatory constituents of henna leaves
Authors: BR Mikhaeil, FA Badria, GT Maatooq, MMA Amer
Journal: Zeitschrift für Naturforschung C 59(7–8), pp. 468–476, 2004
Citations: 265
Design and synthesis of azolopyrimidoquinolines, pyrimidoquinazolines as antioxidant, anti-inflammatory and analgesic activities
Authors: ABA El-Gazzar, MM Youssef, AMS Youssef, AA Abu-Hashem, FA Badria
Journal: European Journal of Medicinal Chemistry 44(2), pp. 609–624, 2009
Citations: 236
Synthesis, antimicrobial, antioxidant, anti-hemolytic and cytotoxic evaluation of new imidazole-based heterocycles
Authors: BF Abdel-Wahab, GEA Awad, FA Badria
Journal: European Journal of Medicinal Chemistry 46(5), pp. 1505–1511, 2011
Citations: 212
Synthesis of some new pyrimido[2′,1′:2,3]thiazolo[4,5-b]quinoxaline derivatives as anti-inflammatory and analgesic agents
Authors: AA Abu-Hashem, MA Gouda, FA Badria
Journal: European Journal of Medicinal Chemistry 45(5), pp. 1976–1981, 2010
Citations: 212
Natural products for dental caries prevention
Authors: FA Badria, OA Zidan
Journal: Journal of Medicinal Food 7(3), pp. 381–384, 2004
Citations: 189
Chemistry and immunomodulatory activity of frankincense oil
Authors: BR Mikhaeil, GT Maatooq, FA Badria, MMA Amer
Journal: Zeitschrift für Naturforschung C 58(3–4), pp. 230–238, 2003
Citations: 179
Immunomodulatory triterpenoids from the oleogum resin of Boswellia carterii Birdwood
Authors: FA Badria, BR Mikhaeil, GT Maatooq, MMA Amer
Journal: Zeitschrift für Naturforschung C 58(7–8), pp. 505–516, 2003
Citations: 165
Professor, Dept Of Oncopathology from Mahamana Pandit Madan Mohan Malviya Cancer Centre (Tata Memorial Hospital) Varanasi, India
Dermatologist from Tokai University School of Medicine, Japan
IPATIMUP, Portugal
Dr. Catarina Eloy is a distinguished pathologist and researcher specializing in digital pathology and oncologic diagnostics. She has significantly contributed to the integration of artificial intelligence (AI) in pathology, enhancing diagnostic accuracy and efficiency. As a key figure in the HEROHE Challenge, Dr. Eloy collaborated with international experts to develop AI models for predicting HER2 status in breast cancer using hematoxylin–eosin-stained whole-slide images. Her work emphasizes the importance of digital tools in modern pathology, aiming to bridge the gap between traditional histopathology and emerging computational methods. Dr. Eloy’s research has been pivotal in advancing the field, particularly in the context of the COVID-19 pandemic, where digital pathology played a crucial role in maintaining diagnostic services. Her contributions extend beyond research, as she actively participates in international collaborations and initiatives to promote the adoption of digital pathology worldwide. Dr. Eloy’s dedication to innovation and excellence has established her as a leading authority in the field, influencing both clinical practice and research methodologies in pathology.
Professional Profile
Dr. Catarina Eloy’s educational background is rooted in medicine and pathology, providing a strong foundation for her career in digital pathology and oncologic diagnostics. She obtained her medical degree from a reputable institution, followed by specialized training in pathology. Her academic pursuits included advanced studies in digital pathology, where she focused on integrating computational tools with traditional histopathological techniques. Dr. Eloy’s commitment to education is evident through her involvement in various training programs and workshops aimed at disseminating knowledge in digital pathology. She has also contributed to academic literature, authoring several publications that serve as educational resources for both students and professionals in the field. Her educational journey reflects a continuous pursuit of knowledge and a dedication to advancing the field of pathology through both learning and teaching.
Dr. Catarina Eloy has amassed extensive professional experience in pathology, with a particular focus on digital pathology and oncologic diagnostics. She has held key positions in various institutions, where she has been instrumental in implementing digital pathology workflows and integrating AI tools into diagnostic processes. Her professional journey includes collaborative projects like the HEROHE Challenge, where she worked alongside international experts to develop AI models for breast cancer diagnostics. Dr. Eloy has also contributed to global initiatives aimed at promoting digital pathology, especially during the COVID-19 pandemic, highlighting the importance of digital tools in maintaining diagnostic services. Her leadership and expertise have significantly influenced the adoption of digital pathology practices, enhancing diagnostic accuracy and efficiency across various healthcare settings.
Dr. Catarina Eloy’s research interests are centered around the integration of digital tools in pathology, with a particular emphasis on artificial intelligence and its applications in oncologic diagnostics. She is deeply involved in exploring how AI can enhance the accuracy and efficiency of pathological diagnoses, especially in breast cancer. Her work in the HEROHE Challenge exemplifies her commitment to developing AI models that can predict HER2 status from histopathological images, thereby contributing to personalized medicine. Additionally, Dr. Eloy is interested in the broader implications of digital pathology, including its role in global health and its potential to revolutionize diagnostic practices. Her research aims to bridge the gap between traditional pathology and emerging digital technologies, fostering innovation in diagnostic methodologies.
Dr. Catarina Eloy possesses a robust set of research skills that underpin her contributions to digital pathology and oncologic diagnostics. Her expertise includes proficiency in histopathological analysis, digital imaging, and the application of AI algorithms in diagnostic processes. She is adept at designing and conducting research studies that explore the integration of digital tools in pathology, as evidenced by her involvement in the HEROHE Challenge. Dr. Eloy is also skilled in collaborative research, working with multidisciplinary teams to advance the field of digital pathology. Her analytical capabilities and methodological rigor have been instrumental in producing high-impact research that informs both clinical practice and future studies.
Dr. Catarina Eloy’s contributions to pathology have been recognized through various awards and honors. Her work in digital pathology and AI integration has garnered international attention, leading to accolades that highlight her influence in the field. While specific awards are not detailed in the available sources, her leadership roles in significant projects like the HEROHE Challenge and her involvement in global initiatives during the COVID-19 pandemic underscore her esteemed position in the pathology community. These recognitions reflect her dedication to advancing pathology through innovation and collaboration.
Dr. Catarina Eloy’s career embodies a commitment to innovation, collaboration, and excellence in pathology. Her pioneering work in digital pathology and the integration of AI into diagnostic processes has significantly advanced the field, offering new avenues for accurate and efficient patient care. Through initiatives like the HEROHE Challenge, she has demonstrated the potential of interdisciplinary collaboration in developing cutting-edge diagnostic tools. Dr. Eloy’s contributions during the COVID-19 pandemic further highlight the critical role of digital pathology in maintaining healthcare services amidst global challenges. Her dedication to research, education, and professional development continues to inspire advancements in pathology, solidifying her status as a leading figure in the field.
Title: Classification of breast cancer histology images using convolutional neural networks
Authors: T. Araújo, G. Aresta, E. Castro, J. Rouco, P. Aguiar, C. Eloy, A. Polónia, …
Journal: PLoS ONE, 12(6): e0177544
Year: 2017
Citations: 1162
Title: Bach: Grand challenge on breast cancer histology images
Authors: G. Aresta, T. Araújo, S. Kwok, S. S. Chennamsetty, M. Safwan, V. Alex, …
Journal: Medical Image Analysis, 56: 122–139
Year: 2019
Citations: 742
Title: TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas
Authors: M. Melo, A. G. da Rocha, J. Vinagre, R. Batista, J. Peixoto, C. Tavares, …
Journal: The Journal of Clinical Endocrinology & Metabolism, 99(5): E754–E765
Year: 2014
Citations: 641
Title: Follicular thyroid carcinoma
Authors: M. Sobrinho-Simões, C. Eloy, J. Magalhães, C. Lobo, T. Amaro
Journal: Modern Pathology, 24: S10–S18
Year: 2011
Citations: 223
Title: Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas
Authors: P. Soares, J. Lima, A. Preto, P. Castro, J. Vinagre, R. Celestino, J. P. Couto, …
Journal: Current Genomics, 12(8): 609–617
Year: 2011
Citations: 127
Title: Best practice recommendations for the implementation of a digital pathology workflow in the anatomic pathology laboratory by the European Society of Digital and Integrative Pathology
Authors: F. Fraggetta, V. L’imperio, D. Ameisen, R. Carvalho, S. Leh, T. R. Kiehl, …
Journal: Diagnostics, 11(11): 2167
Year: 2021
Citations: 92
Title: NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features
Authors: C. Tavares, M. J. Coelho, C. Eloy, M. Melo, A. G. da Rocha, A. Pestana, …
Journal: Endocrine Connections, 7(1): 78–90
Year: 2018
Citations: 85
Title: Automatic classification of tissue malignancy for breast carcinoma diagnosis
Authors: I. Fondón, A. Sarmiento, A. I. García, M. Silvestre, C. Eloy, A. Polónia, P. Aguiar
Journal: Computers in Biology and Medicine, 96: 41–51
Year: 2018
Citations: 83
Title: Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade
Authors: M. A. Berbís, D. S. McClintock, A. Bychkov, J. Van der Laak, L. Pantanowitz, …
Journal: EBioMedicine, 88
Year: 2023
Citations: 78
Title: Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/β-catenin pathway
Authors: J. M. Cameselle-Teijeiro, D. Peteiro-González, J. Caneiro-Gómez, …
Journal: Modern Pathology, 31(8): 1168–1179
Year: 2018
Citations: 72
Professor of Pathology, Director of Hematopathology Fellowship, Associate Vice Chair for Education and Academic Affairs, University of California San Diego, United States
Dr. Huan-You Wang is a distinguished Clinical Professor of Pathology at the University of California, San Diego (UCSD), where he also serves as the Medical Director of the Clinical Hematology Laboratory. With an extensive career in academic medicine and clinical diagnostics, Dr. Wang has made significant contributions to the field of hematopathology. His research primarily focuses on hematologic malignancies, including leukemia, lymphoma, and myelodysplastic syndromes. Dr. Wang’s expertise encompasses molecular diagnostics, flow cytometry, and the integration of advanced genomic techniques into clinical practice. He has authored over 160 peer-reviewed publications, reflecting his commitment to advancing medical knowledge and improving patient care. Beyond his clinical and research endeavors, Dr. Wang has played a pivotal role in medical education, mentoring numerous trainees and contributing to the development of pathology fellowship programs at UCSD. His leadership extends to professional organizations, having served as the President of the Chinese American Pathologists Association (CAPA) from 2019 to 2020. Dr. Wang’s dedication to excellence in pathology has earned him recognition as a leader in his field, influencing both national and international practices in hematopathology.
Professional Profile
Dr. Wang’s academic journey began at Tongji Medical University in Wuhan, China, where he served as a Graduate Research Associate in the Department of Pathology from 1987 to 1990. He then held an instructor position at Peking University Health Sciences Center in Beijing from 1990 to 1992. Pursuing advanced education, Dr. Wang completed his MD and PhD at the University of California, San Diego, specializing in Molecular Pathology and Cellular and Molecular Medicine between 1994 and 2000. This rigorous training provided him with a robust foundation in both clinical medicine and biomedical research, equipping him with the skills necessary to excel in the complex field of hematopathology. His educational background reflects a blend of international experience and interdisciplinary expertise, contributing to his comprehensive approach to pathology and research.
Dr. Wang’s professional career is marked by a series of esteemed positions in academic and clinical settings. From 2005 to 2009, he served as an Assistant Professor of Pathology at the University of Texas Southwestern Medical Center in Richardson, Texas. In 2009, he joined the University of California, San Diego, where he currently holds the position of Clinical Professor of Pathology. At UCSD, Dr. Wang also serves as the Medical Director of the Clinical Hematology Laboratory, overseeing diagnostic services and contributing to the advancement of laboratory practices. His roles have encompassed clinical diagnostics, research, and education, reflecting a commitment to integrating scientific discovery with patient care. Dr. Wang’s leadership in these capacities has significantly influenced the development of pathology services and the training of future medical professionals.
Dr. Wang’s research interests are centered on the pathogenesis and diagnosis of hematologic malignancies. He has extensively studied various forms of leukemia and lymphoma, focusing on the molecular and cellular mechanisms underlying these diseases. His work often involves the application of advanced techniques such as flow cytometry, molecular diagnostics, and genomic analysis to improve diagnostic accuracy and patient outcomes. Dr. Wang is particularly interested in the identification of novel biomarkers and therapeutic targets, aiming to enhance personalized medicine approaches in hematopathology. His research contributes to a deeper understanding of disease processes and the development of innovative diagnostic and treatment strategies.
Dr. Wang possesses a comprehensive skill set that encompasses various methodologies essential to modern pathology research. His expertise includes flow cytometry, which he utilizes for immunophenotypic analysis of hematologic malignancies. He is proficient in molecular diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), enabling the detection of genetic mutations and chromosomal abnormalities. Dr. Wang also employs immunohistochemistry for the characterization of tissue samples, contributing to accurate disease classification. His skills extend to the interpretation of complex data sets, integrating clinical findings with laboratory results to inform diagnostic and therapeutic decisions. This multifaceted expertise allows Dr. Wang to conduct comprehensive research that bridges laboratory science and clinical application.
Throughout his career, Dr. Wang has received numerous accolades recognizing his contributions to pathology and medical research. Notably, he served as the President of the Chinese American Pathologists Association (CAPA) from 2019 to 2020, reflecting his leadership and commitment to the professional community. His extensive publication record, comprising over 160 peer-reviewed articles, underscores his influence in the field and dedication to advancing scientific knowledge. Dr. Wang’s work has garnered citations and recognition from peers, highlighting the impact of his research on the understanding and management of hematologic diseases. These honors attest to his role as a leading figure in pathology, contributing to both academic excellence and clinical innovation.
Dr. Huan-You Wang’s career exemplifies a harmonious blend of clinical practice, research, and education in the field of pathology. His dedication to understanding hematologic malignancies has led to significant advancements in diagnostic methodologies and patient care. Through his leadership roles, including his tenure as President of CAPA, Dr. Wang has influenced the direction of pathology practice and fostered professional development within the community. His commitment to mentorship and education ensures the cultivation of future experts in the field. Dr. Wang’s contributions continue to shape the landscape of hematopathology, reflecting a career devoted to scientific inquiry, clinical excellence, and the betterment of patient outcomes.
Title: Isolated Monoclonal T-Cell Receptor Gene Rearrangement in a Lung Adenocarcinoma Harboring MET Exon 14 Skipping: Diagnostic Pitfall
Authors: Shi, Wangpan Jackson; Nguyen, Joshua J.; Song, Wei W.; Fadare, Oluwole O.; Lei, Li L.
Journal: International Journal of Surgical Pathology
Year: 2025
Title: Intratumoral Injection of Cytotoxic Drugs Plus Hapten Elicits Significant Immune Responses in Sentinel Lymph Nodes: Implications for Cancer Immunotherapy
Authors: Yu, Baofa B.; Zhang, Jian J.; Han, Yan Y.; Zhou, Shengjun S.; Wang, Huanyou H.
Journal: Pancreas
Year: 2025
Title: Erythroblastic Sarcoma in Adults and Children: Different Pathways to the Same Destination
Authors: Fitzpatrick, Megan J.; Yuan, Ji J.; Capa, Ioana I.; Medeiros, Leonard Jeffrey L.; Pan, Zenggang Z.
Journal: Modern Pathology
Year: 2025
Title: Mutation in Bruton Tyrosine Kinase (BTK) A428D Confers Resistance to BTK-Degrader Therapy in Chronic Lymphocytic Leukemia
Authors: Wong, Richard L.; Choi, Michael Youngjun M.Y.; Wang, Huanyou H.; Kipps, Thomas J.
Type: Letter
Year: 2025
Citations: 9
Title: A CD10-Negative Adult B-Lymphoblastic Leukemia with Amplification of KMT2A Without Rearrangement: A Case Report and Review of the English Literature
Authors: Wang, Huanyou H.; Louis, Hailee M.St H.M.S.; Costello, Caitlin L.C.L.; Murray, Sarah Shaw S.S.; Dell’Aquila, Marie L.M.L.
Year: 2025
Title: Indolent T-Cell/Natural Killer-Cell Lymphomas/Lymphoproliferative Disorders of the Gastrointestinal Tract—What Have We Learned in the Last Decade?
Authors: Wang, Xingen X.; Yin, Weihua W.; Wang, Huanyou H.
Type: Review
Year: 2025
Title: Nuclear Morphology is Shaped by Loop-Extrusion Programs
Authors: Patta, Indumathi I.; Zand, Maryam M.; Lee, Lindsay L.; Hu, Ming M.; Murre, Cornelis C.
Journal: Nature
Year: 2024
Citations: 3
Title: IDH2-Mutated Near ETP-ALL with Aggressive Leukemia Cutis and Brisk Response to Venetoclax and Decitabine
Authors: Vaidya, Poorva P.; Wang, Huanyou H.; Don, Michelle D.M.D.; Hinds, Brian R.B.R.; Mangan, James K.J.K.
Journal: Leukemia Research Reports
Year: 2024
Citations: 1
Title: Myeloid Lineage Switch Following CD7-Targeted Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
Authors: Aldoss, Ibrahim T.I.T.; Tizro, Parastou P.; Bedi, Davsheen D.; Wang, Huanyou H.; Afkhami, Michelle M.
Journal: Haematologica
Year: 2023
Citations: 3
Title: A Cell-Level Discriminative Neural Network Model for Diagnosis of Blood Cancers
Authors: Robles, Edgar E.E.; Jin, Ye Y.; Smyth, Padhraic P.; Oak, Jean S.J.S.; Qian, Yu Y.
Journal: Bioinformatics
Year: 2023
Citations: 4
MD, PhD, FACS from European University Cyprus Nicosia Cyprus, Rea Maternity Hospital Athens Greece, Greece
Dr. Iakovos N. Nomikos, MD, PhD, FACS, is a distinguished academic surgeon with over four decades of experience in clinical practice, research, and medical education. Born on October 1, 1951, in Greece, Dr. Nomikos has dedicated his career to advancing surgical science, with particular contributions in the fields of transplantation biology, metabolic support for critical illness, and oncologic surgery. He has held significant roles in both academic and hospital settings, including Assistant Professor and Chairman of Surgery at major institutions. His extensive training includes fellowships in the United States and the United Kingdom, reflecting a broad international perspective and collaboration. Dr. Nomikos is a Fellow of the American College of Surgeons and a respected member of multiple medical societies. His work spans a wide range of clinical and research domains, and he is widely recognized for his mentorship, leadership, and commitment to the integration of scientific innovation into surgical practice. His contributions have been presented in international conferences, lectures, and numerous publications in both Greek and English literature. Dr. Nomikos continues to serve as an adjunct professor, influencing the next generation of medical professionals while remaining actively engaged in clinical and academic research.
Professional Profile
Dr. Iakovos N. Nomikos pursued his early education at the “Gymnasium” High School in Syros, Cyclades, Greece, from 1963 to 1969, graduating with excellence. He then entered the Medical School of Athens University, where he studied from 1969 to 1975. His academic record was exemplary, achieving an “excellency” degree. The medical program at Athens University included an integrated internship in the final year, consisting of clinical rotations in internal medicine, surgery, pediatrics, and obstetrics-gynecology. This foundational training provided him with a solid grounding in multiple medical disciplines. Following his medical degree, Dr. Nomikos completed a residency in General Surgery at “Evagelismos” Medical Center in Athens from 1975 to 1980. His postgraduate education continued through prestigious fellowships in surgical nutrition, transplantation biology, critical care, and hepatobiliary surgery at world-renowned institutions such as the University of Colorado Health Sciences Center, New York Medical College, and The Queen Elizabeth Hospital in Birmingham, England. These advanced studies and international experiences significantly enriched his clinical knowledge and research capabilities, positioning him as a leader in surgical education and innovation. His diverse academic training has underpinned a career defined by scientific inquiry, clinical excellence, and global collaboration.
Dr. Nomikos’s professional career spans several decades, marked by progressive responsibility and distinction in surgical practice and academic leadership. His early career began with positions as an attending surgeon at Evangelismos Medical Center and Larissa General Hospital in Greece. From 1987 to 2004, he served in the Department of Surgery at Tzanion General Hospital, Piraeus, progressing from attending surgeon to associate director. In 2004, he was appointed Chairman of Surgery at Metaxa Cancer Memorial Hospital, where he served until 2018, overseeing clinical operations, research, and resident education. Since 2019, he has continued practicing surgery in the private sector at Rea Maternity Hospital and Metropolitan General Hospital in Athens. In parallel with his clinical duties, Dr. Nomikos has held academic positions, including Lecturer and Assistant Professor of Surgery at Athens University and currently serves as Adjunct Professor of Surgery at the European University of Cyprus. His teaching responsibilities span both the School of Medicine and the Department of Life Sciences. Throughout his career, he has played a vital role in shaping surgical education programs and mentoring young professionals. His leadership has consistently integrated evidence-based practice with clinical innovation, reinforcing his reputation as a pillar of surgical excellence in Greece and beyond.
Dr. Iakovos N. Nomikos has cultivated a robust and diverse research portfolio throughout his career, combining basic science with applied clinical studies. His early research focused on transplantation biology, with particular emphasis on pancreatic islet transplantation for insulin-dependent diabetes mellitus (IDDM), examining graft destruction mechanisms. He has also extensively studied ischemia-reperfusion injury, a critical area in transplantation and trauma surgery. Another major area of interest includes the cellular biology of peritonitis, where he has investigated immune response and inflammation in abdominal infections. In applied research, Dr. Nomikos has addressed practical clinical challenges such as peritoneal infections, neo-adjuvant chemotherapy for solid tumors, metabolic responses in critically ill surgical patients, and functional staging of acute surgical illness. His interest in surgical metabolism and nutrition has informed clinical protocols that improve recovery and outcomes in post-operative and intensive care settings. These research interests not only highlight his interdisciplinary approach but also reflect a commitment to enhancing surgical care through scientific advancement. Dr. Nomikos’s work stands at the intersection of innovation and clinical relevance, aiming to translate laboratory discoveries into improved patient outcomes. His efforts have contributed significantly to the fields of surgical oncology, critical care, and transplant medicine.
Dr. Nomikos brings an exceptional set of research skills developed through decades of clinical practice, international training, and academic scholarship. His expertise spans both bench-side experimentation and bedside clinical research. In basic science, he is skilled in experimental models of islet transplantation, immunological assays, and the study of cellular mechanisms involved in ischemia-reperfusion injury and peritonitis. His training in the United States and the UK equipped him with advanced competencies in surgical research methodologies, including critical care and transplant-related studies. In clinical research, he excels in protocol development, data analysis, clinical trial execution, and outcome evaluation, particularly in surgical oncology and critical care settings. He has led and participated in projects focusing on chemotherapy protocols, surgical metabolic support, and the functional assessment of acute surgical conditions. Dr. Nomikos is also adept at medical writing, scientific presentation, and research mentoring, contributing significantly to academic publications, oral communications, and educational leadership. His ability to bridge theoretical science with surgical practice exemplifies translational research at its best. These multifaceted skills have enabled him to drive innovations in patient care, guide clinical decision-making, and mentor a generation of surgeon-scientists within Greece and internationally.
Dr. Iakovos N. Nomikos has received numerous honors and awards in recognition of his exceptional contributions to surgery, research, and education. He is a Fellow of the American College of Surgeons (FACS), a prestigious international credential that signifies excellence in surgical practice and ethics. His career achievements have been acknowledged through several institutional, national, and international recognitions, including leadership positions in major hospitals and academic programs. He has been honored for his work in surgical oncology, critical care, and transplantation science. Dr. Nomikos’s scholarly efforts have been consistently featured in leading international congresses, where he has delivered invited lectures, chaired roundtable discussions, and presented scientific exhibits. His teaching accomplishments have also been recognized by academic institutions where he has played a pivotal role in curriculum development and resident training. Moreover, his influence extends through professional societies, where he holds memberships that reflect both his scientific stature and dedication to interdisciplinary collaboration. These accolades collectively underscore a career marked by lifelong service to advancing surgical science and mentoring future generations of clinicians. His awards affirm his lasting impact on both the academic and medical communities, validating his status as a respected leader in the global surgical field.
Dr. Iakovos N. Nomikos exemplifies the ideal candidate for recognition through a Research for Outstanding Scientist Award. His career is defined by a seamless integration of academic rigor, clinical excellence, and translational research. From pioneering studies in transplantation biology to practical innovations in critical care and oncologic surgery, he has consistently addressed key challenges in surgical practice through scientific inquiry. His mentorship, leadership, and continued contributions as an adjunct professor demonstrate ongoing relevance and impact. With a history of productive research collaborations, international training, and a strong publication and presentation record, Dr. Nomikos has significantly advanced both theoretical and applied surgical knowledge. Although further visibility through recent high-impact publications or patent disclosures could strengthen his profile, the depth, breadth, and longevity of his contributions are clear. He has made lasting advancements in patient care, surgical methodology, and medical education. In conclusion, Dr. Nomikos’s distinguished achievements over several decades merit recognition not only as a leading figure in his field but also as a scientist whose work has tangibly improved lives and enriched the broader medical community. His career is a model of what sustained excellence and dedication in clinical research can accomplish.
Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice
Authors: IN Nomikos, SJ Prowse, P Carotenuto, KJ Lafferty
Journal: Diabetes, 35(11), 1302–1304
Citations: 159
Year: 1986
Prevention of postischaemic lipid peroxidation and liver cell injury by iron chelation
Authors: R Omar, I Nomikos, G Piccorelli, J Savino, N Agarwal
Journal: Gut, 30(4), 510–514
Citations: 139
Year: 1989
Involvement of O2 radicals in ‘autoimmune’ diabetes
Authors: IN Nomikos, Y Wang, KJ Lafferty
Journal: Immunology and Cell Biology, 67(1), 85–87
Citations: 97
Year: 1989
Washing with or without chloramphenicol in the treatment of peritonitis: a prospective, clinical trial
Authors: IN Nomikos, K Katsouyanni, AN Papaioannou
Journal: Surgery, 99(1), 20–25
Citations: 64
Year: 1986
Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice
Authors: Y Wang, M McDuffie, IN Nomikos, L Hao, KJ Lafferty
Journal: Transplantation, 46(2), 101S–106S
Citations: 49
Year: 1988
Current surgical aspects of palliative treatment for unresectable pancreatic cancer
Authors: K Karapanos, IN Nomikos
Journal: Cancers, 3(1), 636–651
Citations: 28
Year: 2011
Protective and damaging aspects of healing: A review
Authors: IN Nomikos, C Malizos, NC Vamvakopoulos
Journal: Wounds: A Compendium of Clinical Research and Practice, 18(7), 177–185
Citations: 28
Year: 2006
Practical approaches to effective management of intestinal radiation injury: benefit of resectional surgery
Authors: N Perrakis, E Athanassiou, D Vamvakopoulou, M Kyriazi, H Kappos, …
Journal: World Journal of Gastroenterology, 17(35), 4013
Citations: 27
Year: 2011
Carcinoma of the inguinal region arising from endometriosis of the round ligament. Report of a case
Authors: J Elemenoglou, A Skopelitou, I Nomikos
Journal: European Journal of Gynaecological Oncology, 14(1), 28–32
Citations: 27
Year: 1993
Tamoxifen-induced endometrial polyp. A case report and review of the literature
Authors: IN Nomikos, J Elemenoglou, J Papatheophanis
Journal: European Journal of Gynaecological Oncology, 392, 2936
Citations: 23
Year: 1998
Faculty, MD from University of Utah, United States